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        Introduction 
 Integrins  are    /   -heterodimeric receptors that mediate cell  –
    matrix and cell  –  cell adhesion through interactions with extra-
cellular adhesive ligands and cellular counterreceptors (  Hynes, 
2002  ). Ligand binding to many, if not most, integrins is regu-
lated by inside-out signaling. In this process, occupancy of cell 
surface agonist receptors (e.g., G protein  –  coupled receptors and 
receptor protein tyrosine kinases) initiates intracellular signaling 
to activate integrins. Ultimately, activation signals are thought 
to converge on the integrin      and/or      cytoplasmic  domains, 
leading to conformational changes that are propagated to the 
transmembrane and extracellular domains to increase receptor 
affi  nity (  Calderwood, 2004  ;   Ginsberg et al., 2005  ;   Luo et al., 2007  ). 
In platelets, affi  nity modulation regulates the interaction of    IIb  3 
with cognate ligands, including fi  brinogen, von Willebrand fac-
tor, and fi  bronectin, leading to platelet spreading and aggre-
gation at sites of vascular damage (  Shattil and Newman, 2004; 
Jackson, 2007  ). In humans, abnormalities in inside-out signaling 
may cause either reduced platelet adhesive function and bleed-
ing (  Chen et al., 1992  ;   Wang et al., 1997; Pasvolsky et al., 2007  ) 
or heightened platelet function and thrombosis (  Ruggeri, 2002; 
Michiels et al., 2006  ). Consequently, substantial efforts have 
been made to unravel the molecular mechanisms of inside-out 
signaling in platelets and other cells, with recent studies focus-
ing on candidate proteins that may interact with the integrin cyto-
plasmic domains to fl  ip the activation switch (  Liu et al., 2000; 
Ginsberg et al., 2005  ;   Leisner et al., 2007  ). 
  Talin1 (talin) is an     270-kD protein with an N-terminal 
globular head and a C-terminal rodlike tail (  Critchley, 2004  ). 
The talin head contains a FERM domain capable of engaging 
several proteins, including integrin      cytoplasmic domains, and 
the talin rod contains a second integrin-binding site and binding 
sites for fi  lamentous actin and vinculin (  Knezevic et al., 1996; 
Critchley, 2004  ). Overexpression of the talin head or FERM 
domain promotes activation of    IIb   3 and other integrins in 
model cell systems (  Calderwood et al., 1999; Bouaouina et al., 
2008  ). Talin knockout in the mouse is embryonic lethal (  Monkley 
et al., 2000  ). However, knockdown of talin in megakaryocyte 
platelet precursors with short hairpin RNA (shRNA;   Tadokoro 
et al., 2003  ) and hematopoietic- or platelet/megakaryocyte-specifi  c 
  P
latelet aggregation requires agonist-induced     IIb    3 
activation, a process mediated by Rap1 and talin. 
To study mechanisms, we engineered     IIb    3 Chinese 
hamster ovary (CHO) cells to conditionally express talin 
and protease-activated receptor (PAR) thrombin receptors. 
Human PAR1 or murine PAR4 stimulation activates     IIb    3, 
which was measured with antibody PAC-1, indicating 
complete pathway reconstitution. Knockdown of Rap1  –
  guanosine triphosphate  –  interacting adaptor molecule 
(RIAM), a Rap1 effector, blocks this response. In living 
cells, RIAM overexpression stimulates and RIAM knockdown 
blocks talin recruitment to     IIb    3, which is monitored by 
bimolecular ﬂ  uorescence complementation. Mutations in 
talin or     3 that disrupt their mutual interaction block 
both talin recruitment and     IIb    3 activation. However, 
one talin mutant (L325R) is recruited to     IIb    3 but cannot 
activate it. In platelets, RIAM localizes to ﬁ  lopodia and 
lamellipodia, and, in megakaryocytes, RIAM knock-
down blocks PAR4-mediated     IIb    3 activation. The RIAM-
related protein   lamellipodin promotes talin recruitment and 
    IIb    3 activity in CHO cells but is not expressed in mega-
karyocytes or platelets. Thus, talin recruitment to     IIb    3 
by RIAM mediates agonist-induced     IIb    3 activation, with 
implications for hemostasis and thrombosis.
  Mechanisms and consequences of agonist-induced 
talin recruitment to platelet integrin     IIb    3 
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  Figure 1.       Talin recruitment to     IIb    3 can be visualized in living cells by BiFC.   (A) Principle of BiFC. The top panel depicts the two fusion proteins,     IIb-VC 
and VN-talin, used for BiFC. Also depicted are wild-type     3 and     3 (    724), which were cotransfected into CHO cells with     IIb-VC to enable the expression 
of     IIb-VC    3 and     IIb-VC    3 (    724), respectively. TM, transmembrane domain. The bottom panel illustrates the concept of BiFC when VN-talin successfully 
interacts with     IIb-VC    3 as the result of inside-out signaling. See Results for further discussion. (B) Flow cytometry with antibody D57 was used to determine 
    IIb    3 surface expression in cells stably transfected with     IIb    3,     IIb-VC    3, or     IIb-VC    3 (    724). Parental CHO cells were used as a negative control. 
Expression of the chimeric integrins was equivalent to that of wild-type     IIb    3. (C) Western blotting illustrates the molecular sizes of the     IIb and     3 sub-
units obtained from cells shown in B. (D) VN-talin complements Venus ﬂ  uorescence better than talin-VC. The N-terminal half of Venus was fused to either 1213  RIAM, TALIN, AND INTEGRIN ACTIVATION   • Watanabe et al. 
the talin N terminus (VN-talin) or the talin C terminus (talin-VN) and transiently transfected into     IIb-VC    3 cells. BiFC was then measured by ﬂ  ow cytometry. 
The same experiment was performed in parallel with     IIb-VC    3 (    724) cells, which lack a major talin interaction site in     3. Data are means   ±   SEM (error 
bars) of three experiments. (E)     IIb-VC    3  –  CHO cells and     IIb-VC    3 (    724)  –  CHO cells were cotransfected with VN-talin and Rap1a (V12). 48 h later, 
cells were plated on ﬁ  brinogen for 60 min, ﬁ  xed, and analyzed by deconvolution microscopy. Note that in the     IIb-VC    3 cells, BiFC ﬂ  uorescence (green) 
was colocalized with vinculin (red) to lamellipodial edges (arrow), focal complexes (arrowheads), and focal adhesions (double arrowhead). Only minor 
colocalization was noted in the     IIb-VC    3 (    724) cells. Bars, 10   μ  m.     
 
talin knockout in mice (  Nieswandt et al., 2007  ;   Petrich et al., 
2007b  ) cause severe impairment of agonist-induced    IIb  3 
  activation and a bleeding diathesis. In unstimulated platelets, 
talin resides in the cytoplasm (  Bertagnolli et al., 1993  ), pre-
sumably in an autoinhibited conformation, with the head and 
tail interacting in an intra- or intermolecular fashion to limit 
access to binding proteins (  Calderwood, 2004  ;   Critchley, 2005  ; 
  Ginsberg et al., 2005  ). Platelet stimulation by thrombin or other 
agonists is hypothesized to relieve this autoinhibition and pro-
mote talin recruitment to and activation of    IIb  3.  However, 
several critical details of talin  ’  s function in platelets and other 
cells remain sketchy, particularly the process of talin recruit-
ment to activate integrins. 
  Among the proteins that have been implicated in integrin-
mediated cell adhesion are the Rap1 GTPase (  Bos, 2005  ) and 
Rap1-GTP  –  interacting adaptor molecule (RIAM), a Rap1 ef-
fector (  Lafuente et al., 2004  ). RIAM is a member of the MRL 
family of adaptor molecules that includes lamellipodin and its 
  Caenorhabditis elegans   orthologue, Mig-10 (  Krause et al., 2004  ; 
  Lafuente et al., 2004; Chang et al., 2006  ). Each contains an 
N-terminal coiled-coil region, central Ras association and pleck-
strin homology domains, a proline-rich C-terminal region, and 
multiple FPPPP motifs capable of interacting with the EVH1 do-
mains of the actin regulatory proteins Ena/vasodilator-stimulated 
phosphoprotein (VASP). RIAM but not lamellipodin interacts 
with Rap1-GTP to promote the adhesion of Jurkat T cells through 
    1 and     2 integrins (  Krause et al., 2004  ;   Lafuente et al., 2004  ). 
Lamellipodin, on the other hand, promotes lamellipodia forma-
tion through Ena/VASP ( Krause et al., 2004 ), and Mig-10 promotes 
axon guidance and outgrowth through the Ena/VASP homologue, 
unc-34 (  Chang et al., 2006  ). 
  Recent evidence supports roles for both Rap1 and RIAM 
in    IIb  3  affi  nity modulation. Knockdown or knockout of Rap1b 
(  Chrzanowska-Wodnicka et al., 2005  ) or of CalDAG-GEFI, a 
Rap1 exchange factor (  Eto et al., 2002; Crittenden et al., 2004  ), 
is associated with defective agonist-induced    IIb  3  activation. 
Furthermore, overexpression of activated Rap1a (V12) or RIAM 
in CHO cells leads to talin-dependent    IIb   3 activation as mea-
sured with the ligand-mimetic antibody PAC-1. In contrast, 
knockdown of either protein by shRNA has the opposite effect 
(  Han et al., 2006  ). Interestingly, Rap1a (V12) promotes RIAM 
association with talin, as determined indirectly by coimmuno-
precipitation and immunofl  uorescence colocalization techniques. 
However, it remains to be determined whether RIAM promotes 
talin recruitment directly to    IIb   3 in living cells, whether it 
mediates inside-out signaling in response to a platelet agonist, 
and whether it regulates integrin activation in platelets or mega-
karyocytes. Moreover, a role for lamellipodin, if any, in    IIb  3 
activation has not been addressed. In this study, we have resolved 
these issues by using bimolecular fl  uorescence complementation 
(BiFC;   Kerppola, 2008  ) to monitor talin recruitment to    IIb  3 
in living cells and by studying RIAM  –  talin  –     IIb  3  relation-
ships in platelets and megakaryocytes. The results establish that 
RIAM but not lamellipodin is a central player in agonist-induced 
recruitment of talin to    IIb   3. Furthermore, a specifi  c inter-
action between the talin FERM domain and     3 is required for 
the recruited talin to activate    IIb  3. 
  Results 
  Talin recruitment to     IIb    3 in living cells 
  To study the process of talin recruitment to    IIb   3, we devel-
oped a method to monitor specifi  c, proximal interactions be-
tween full-length talin and    IIb   3 in living cells based on BiFC 
(  Shyu et al., 2006; Kerppola, 2008  ). Two chimeras were con-
structed for this purpose (  Fig. 1 A  ). One, VN-talin, consists of 
the N-terminal half of the Venus fl  uorophore fused to the N ter-
minus of mouse talin. The other chimera,    IIb-VC,  consists  of 
the C-terminal half of Venus fused to the C terminus of human 
    IIb. The latter was cotransfected with human    3  to  establish 
stable cell lines expressing    IIb-VC   3. We reasoned that after 
transfection of VN-talin into these cells, this protein would be 
recruited from the cytoplasm to    IIb-VC   3 in response to an 
inside-out stimulus. Assuming proper orientation, the split Venus 
moieties associated with talin and    IIb   3 would then interact 
and refold to complement Venus fl  uorescence (  Fig. 1 A  ). On the 
other hand, fl  uorescence complementation would be reduced 
in cells that express a     3 deletion mutant (   3     724) that lacks 
the NPXY interaction site for the talin FERM domain (  Wegener 
et al., 2007  ). Therefore, each experiment included cells express-
ing    IIb-VC  3  (   724) as a control for fl  uorescence unrelated 
to this specifi  c talin  –     3  interaction. 
  Cell lines expressing    IIb-VC  3  or    IIb-VC  3  (  724) 
showed integrin surface expression profi  les that were equivalent 
to that of a cell line expressing    IIb   3 (  Fig. 1 B  ). Furthermore, 
the    IIb-VC,     3, and    3  (   724) subunits each migrated as ex-
pected in Western blots of cell lysates (  Fig. 1 C  ). We chose VN-
talin for these studies rather than placing VN at the C terminus 
of talin (talin-VN) because in preliminary studies, overexpres-
sion of VN-talin in   IIb-VC  3 cells consistently yielded greater 
fl  uorescence complementation than did talin-VN (  Fig. 1 D  ). 
This may be explained by the fact that in VN-talin, the split fl  uo-
rophore is contiguous with the talin FERM domain rather than 
with the rodlike tail. The fl  uorescence complementation we ob-
served between VN-talin and    IIb-VC   3 in the absence of an 
inside-out stimulus is likely the result of overexpression and/or 
stabilization of the VN/VC pair, as seen in a previous study 
  using BiFC (  Kerppola, 2008  ). To further validate the BiFC ap-
proach, cells transiently transfected with VN-talin were allowed 
to bind to immobilized fi  brinogen, which activates    IIb  3 JCB • VOLUME 181 • NUMBER 7 • 2008  1214 
VC    3 cells were cotransfected with constitutively active Rap1a 
(V12) and VN-talin, they exhibited signifi  cant increases in BiFC 
and PAC-1 binding when compared with the same cells not trans-
fected with VN-talin (  Fig. 2 A  ). In contrast,    IIb-VC  3  (  724) 
cells transfected with Rap1a (V12) and VN-talin showed lower 
fl  uorescence complementation and no increase in PAC-1 binding. 
VN-talin expression was similar in both cell lines (  Fig. 2 A  ). 
BiFC involving VN-talin and    IIb-VC   3 did not require the 
presence of an    IIb   3 ligand, such as fi  brinogen or PAC-1. 
Thus, Rap1a induces both talin recruitment and    IIb  3  activa-
tion. To determine whether talin recruitment is necessary and 
suffi  cient for    IIb   3 activation, we tested talin FERM domain 
  directly (  Du et al., 1991  ) and promotes cell spreading. Fixed and 
stained    IIb-VC   3  –  CHO cells were well spread, and BiFC was 
prominent at vinculin-rich lamellipodial edges, focal complexes, 
and focal adhesions (  Fig. 1 E  ). In contrast,    IIb-VC  3  (  724) 
cells spread poorly and exhibited only minor colocalization 
of BiFC and vinculin at focal adhesions (  Fig. 1 E  ). No BiFC was 
observed if VN-talin or    IIb-VC   3 was expressed independently. 
These results indicate that VN-talin can interact specifi  cally 
with    IIb-VC   3 and at suffi  cient proximity to monitor talin inter-
action with    IIb  3. 
  Next, we asked whether inside-out signals can lead to 
  activation of    IIb   3 by recruiting talin to the integrin. When    IIb-
  Figure 2.       Structural requirements in talin and     3 for talin recruitment and inside-out     IIb    3 activation in living cells.   (A) Effects of talin mutation on BiFC 
and PAC-1 binding. VN-talin (either wild-type, L325R, or W359A talin) was cotransfected with Rap1a (V12) into CHO cells expressing     IIb-VC    3 or 
    IIb-VC    3 (    724). As a control, cells were transfected with Rap1a (V12) but not VN-talin (white bars). 48 h later, BiFC ﬂ  uorescence, PAC-1 binding, and 
talin expression in transfected cells were quantiﬁ  ed by ﬂ  ow cytometry as described in Materials and methods. Responses are expressed as fold increase 
compared with cells not transfected with VN-talin. (B) Effects of     3 mutation on BiFC and PAC-1 binding. VN-talin was cotransfected with Rap1a (V12) 
into CHO cells expressing     IIb-VC    3,     IIb-VC    3 (Y747A), or     IIb-VC    3 (    724). As a control, cells were transfected with empty vector (mock). 48 h later, 
BiFC ﬂ  uorescence, PAC-1 binding, and talin expression in transfected cells were quantiﬁ  ed by ﬂ  ow cytometry. Responses are expressed as fold increase 
compared with mock controls. (A and B) Data are means   ±   SEM (error bars) of four experiments.     1215  RIAM, TALIN, AND INTEGRIN ACTIVATION   • Watanabe et al. 
may be explained by the fact that, unlike RIAM, lamellipodin 
does not interact with Rap1-GTP as a typical effector (  Krause 
et al., 2004  ). 
mutants (L325R and W359A) and a    3  cytoplasmic  domain 
mutant (Y747A), all of which are reported to be defective in 
supporting    IIb   3 activation (  Tadokoro et al., 2003; Petrich 
et al., 2007a  ). However, when cotransfected with Rap1a (V12), 
VN-talin (L325R) was recruited normally to    IIb-VC  3 ( Fig. 2 A ). 
In contrast, both the recruitment of VN-talin (W359A) to    IIb-
VC   3 ( Fig. 2 A ) and recruitment of VN-talin to   IIb  3 (Y747A; 
  Fig. 2 B  ) were signifi  cantly impaired (P   <   0.001). All three mu-
tants failed to support Rap1a (V12)-mediated PAC-1 binding to 
   IIb   3 (P   <   0.001) despite levels of talin expression similar to 
that of    IIb-VC   3 cells transfected with VN-talin (  Fig. 2, A and B  ). 
Thus, talin recruitment appears to be necessary for    IIb  3  acti-
vation in response to an inside-out stimulus such as that imparted 
by activated Rap1a. However, the results with VN-talin (L325R) 
indicate that events subsequent to talin recruitment are also 
needed. Crystallographic experiments (  Wegener et al., 2007  ) 
have shown that the talin FERM domain makes contact with 
membrane-distal residues in the NPXY region of     3, a contact 
disrupted by the talin (W359A) substitution. In contrast, talin 
(L325R) disrupts interaction with the more membrane-proximal 
region of     3. The present results in living cells support speculation 
from the crystallographic experiments (  Wegener et al., 2007  ) 
that after initial talin recruitment to     3 NPXY, additional talin 
interactions with the membrane-proximal region of     3 are re-
quired for integrin activation to proceed. 
  RIAM and lamellipodin in talin recruitment 
and     IIb    3 activation 
  RIAM has been implicated as a Rap1 effector in the    IIb  3 
activation pathway (  Han et al., 2006  ). Therefore, we asked 
whether RIAM promotes talin recruitment to    IIb  3  in  living 
cells and compared its effects with that of the structurally re-
lated MRL protein, lamellipodin (  Krause et al., 2004  ). To facili-
tate these studies, VN-talin was expressed in    IIb-VC  3  cells 
under the control of a tetracycline-regulated promoter. Induc-
tion of talin by doxycycline caused an increase in BiFC and 
PAC-1 binding compared with noninduced cells. However, the 
transient expression of Rap1a (V12), RIAM, or lamellipodin 
caused further increases in BiFC and PAC-1 binding when com-
pared with doxycycline-induced but mock-transfected cells (P   ≤   
0.01;   Fig. 3 A  ). Western blotting of the doxycycline-induced 
cells showed appropriate expression of the transfected recom-
binant proteins and equivalent levels of VN-talin (  Fig. 3 B  ). 
Thus, when overexpressed, activated Rap1a, RIAM, and lamelli-
podin each have the capacity to promote talin recruitment and 
   IIb  3  activation. 
  To evaluate the function of endogenous RIAM or lamelli-
podin  in  VN-talin – expressing    IIb-VC   3 cells, each protein was 
knocked down by shRNA. Compared with control shRNA, RIAM 
or lamellipodin shRNA reduced levels of their respective target 
proteins by     70% without affecting levels of talin (  Fig. 4 A  ). 
This partial knockdown of RIAM but not lamellipodin inhibited 
both basal and Rap1a (V12)-mediated BiFC and PAC-1 binding 
in talin-expressing cells (P   ≤   0.05;   Fig. 4 B  ). These results sug-
gest that talin recruitment and    IIb   3 activation mediated by 
Rap1a (V12) require RIAM but not lamellipodin. The inability 
of lamellipodin knockdown to block the effects of Rap1a (V12) 
  Figure 3.       RIAM and lamellipodin promote talin recruitment and     IIb    3 
activation.   (A)     IIb-VC    3 CHO cells were engineered to conditionally express 
VN-talin under the control of a tetracycline-regulated promoter as described 
in Materials and methods. Cells were then incubated for 24 h in the absence 
(Dox (    )) or presence (Dox (+)) of 0.75 ng/ml doxycycline, a concentra-
tion that induced approximately half-maximal expression of VN-talin. Con-
comitantly, cells were transiently transfected as indicated with empty vector 
(mock) or vectors for Rap1a (V12), RIAM, or lamellipodin (Lpd). Then, BiFC 
and PAC-1 binding were analyzed and expressed as fold increase com-
pared with Dox (    ) mock controls. Data represent means   ±   SEM (error bars) 
of four experiments. Double asterisks indicate means that were signiﬁ  cantly 
different from the Dox (+) mock control at P   ≤   0.01. (B) Protein expression 
was analyzed in cell lysates by Western blotting. Immunoblotting for     -actin 
was used to assess gel loading. A representative Western blot is shown.     JCB • VOLUME 181 • NUMBER 7 • 2008  1216 
  Requirements for reconstitution of agonist-
induced     IIb    3 activation 
   IIb   3-CHO cells, even those overexpressing talin, do not bind 
soluble    IIb   3 ligands when stimulated with thrombin or other 
physiological agonists, indicating that, unlike platelets, agonist-
response coupling is incomplete. In an attempt to engineer agonist 
responsiveness, the human protease-activated receptor 1 (PAR1) 
thrombin receptor and talin were coexpressed in a tetracycline-
regulated fashion. After induction with doxycycline and transfec-
tion of cells with a control shRNA, addition of 0.5 or 50   μ  M 
SFLLRN, a PAR1 agonist peptide, resulted in increased PAC-1 
  Figure 4.       Knockdown of RIAM but not lamellipodin blocks 
  talin recruitment and     IIb    3 activation induced by Rap1a (V12).   
    IIb    3-CHO cells were transduced with lentivirus encoding RIAM-
speciﬁ  c shRNA, lamellipodin-speciﬁ  c shRNA (Lpd), or an irrelevant 
control (CTRL) shRNA. 48 h later, some cells were transfected 
with Rap1a (V12) as indicated, and, 24 h after that, 0.75 ng/ml 
doxycycline was added to induce VN-talin expression. (A) Pro-
tein expression was analyzed in cell lysates by Western blotting. 
(B) BiFC and PAC-1 binding were measured and expressed as 
fold increase compared with noninduced cells (no VN-talin). Data 
are means   ±   SEM (error bars) of three experiments.     
binding (P   <   0.0001;   Fig. 5 A  , Dox (+)). Similar results were ob-
tained if these cells were stimulated with thrombin or if murine 
PAR4 was expressed instead of PAR1 and the cells stimulated 
with AYPGKF, a PAR4 agonist peptide (not depicted). However, 
no signifi  cant    IIb   3 activation in response to SFLLRN was ob-
served in the absence of PAR1 and talin induction (  Fig. 5 A  , Dox 
(    )) or if PAR1 was expressed without talin (not depicted). Thus, 
expression of platelet PAR receptors in CHO cells reconstitutes 
agonist-induced and talin-dependent    IIb  3  activation. 
  To investigate the requirements for endogenous RIAM or 
lamellipodin in agonist-induced    IIb   3 activation, each protein 1217  RIAM, TALIN, AND INTEGRIN ACTIVATION   • Watanabe et al. 
blotting. To study the subcellular localization of RIAM, human 
platelets were plated on fi  brinogen for up to 45 min in the pres-
ence of ADP and epinephrine to enhance spreading, and cells 
were examined by immunofl  uorescence microscopy. As spread-
ing proceeded, RIAM was localized to vinculin-rich fi  lopodia 
and lamellipodial edges (  Fig. 6   A, a  –  d). In fully spread plate-
lets, RIAM localized with vinculin and actin in structures that 
may be the platelet equivalent of focal adhesions (  Fig. 6   A, 
e and f;   Nachmias and Golla, 1991; Leng et al., 1998  ;   Bearer 
et al., 2002  ). 
  To determine whether RIAM is required for inside-out 
signaling in primary cells, megakaryocytes derived from murine 
embryonic stem cells (  Eto et al., 2002  ) were transduced with 
lentivirus encoding RIAM shRNA. This resulted in an    60% 
reduction in immunoreactive RIAM but no change in levels 
of other megakaryocyte proteins, including glycoprotein IX,   
  -actin (  Fig. 6 B  ), and    IIb  3  ( Fig.  6  C ).  Megakaryocytes 
transduced with control shRNA and stimulated with the PAR4 
was knocked down with shRNA. As before, RIAM and lamelli-
podin shRNAs caused a specifi  c     70% reduction in the target 
protein (  Fig. 5 B  ). RIAM knockdown in doxycycline-induced 
cells inhibited PAC-1 binding in response to both low and high 
concentrations of SFLLRN (P   <   0.0001;   Fig. 5 A  ). A second 
RIAM shRNA had the same effect (not depicted). By compari-
son, lamellipodin knockdown appeared less effective in blocking 
PAR1-mediated    IIb   3 activation, reducing PAC-1 binding in 
response to low but not high concentrations of SFLLRN ( Fig. 5 A  ). 
These results indicate that endogenous RIAM is required to 
support full PAR1-mediated, talin-dependent    IIb  3  activation 
in CHO cells. 
  RIAM localization and function in platelets 
and megakaryocytes 
  RIAM is expressed in platelets and megakaryocytes (  Han et al., 
2006  ). However, we have been unable to identify lamellipodin 
in human or mouse platelets or megakaryocytes by Western 
  Figure 5.       Effect of RIAM or lamellipodin knockdown on PAR1-mediated     IIb    3 activation in CHO cells.   (A)     IIb    3-CHO cells were engineered to condi-
tionally express PAR1 and talin under the control of a tetracycline-regulated promoter. Cells were then transduced with lentivirus encoding RIAM shRNA, 
lamellipodin (Lpd) shRNA, or control shRNA (CTRL). After PAR1 and talin induction for 24 h with doxycycline, induced (Dox (+)) and noninduced (Dox (    )) 
cells were incubated for 10 min at room temperature with PAC-1 in the absence or presence of a subsaturating (0.5   μ  M) or saturating (50   μ  M) concentra-
tion of PAR1 agonist peptide, SFLLRN. Then, speciﬁ  c PAC-1 binding to the lentiviral-transduced cells was determined. PAC-1 binding is expressed as fold 
increase compared with unstimulated Dox (    ) cells transduced with control shRNA. Data are means   ±   SEM (error bars) of three experiments. (B) Protein 
expression was analyzed by Western blotting. (C) Flow cytometry histograms depicting surface expression of recombinant PAR1 before (open histograms) 
and after (closed histograms) doxycycline induction detected with an antibody speciﬁ  c for the Flag epitope.     JCB • VOLUME 181 • NUMBER 7 • 2008  1218 
  Discussion 
  In this study, BiFC was used to monitor talin recruitment to 
   IIb   3 in living cells, and the potential mechanisms and con-
sequences of this event were studied. Coupled with studies in 
primary cells and successful reconstitution of agonist-induced 
agonist peptide, AYPGKF, or a combination of AYPGKF, ADP, 
and epinephrine bound 10- and 42-fold more fi  brinogen, re-
spectively, than unstimulated megakaryocytes. RIAM knock-
down inhibited each of these responses signifi  cantly (P   <   0.0001; 
  Fig. 6 D  ). Thus, RIAM is required for normal agonist-induced 
activation of    IIb   3 in primary cells. 
  Figure 6.       Localization and function of RIAM in platelets and 
megakaryocytes.   (A) RIAM localization in platelets. Washed 
human platelets were plated on ﬁ  brinogen for up to 45 min. 
Cells in a  –  c were stained with antibodies to RIAM (red) and 
vinculin (green). Cells in d  –  f were stained for RIAM (green), 
vinculin (blue), and F-actin (red). Platelets were imaged by 
deconvolution microscopy. Each panel represents a platelet 
representative of the range of platelets observed. As spread-
ing proceeded, RIAM was prominent within vinculin-rich 
ﬁ   lopodia (arrows), lamellipodial edges (arrowhead), and 
focal adhesion-like structures (double arrowhead). Bar, 10   μ  m. 
(B  –  D) RIAM is required for agonist-induced     IIb    3 activation 
in primary megakaryocytes. Murine megakaryocytes derived 
from embryonic stem cells were infected with lentivirus encod-
ing control (CTRL) or RIAM shRNA. 7 d later, megakaryocytes 
were evaluated for RIAM expression in cell lysates by Western 
blotting (B),     IIb    3 surface expression by ﬂ  ow cytometry using 
antibody D57 (closed histograms) and an IgG control (open 
histograms; C), and speciﬁ  c ﬁ  brinogen binding by ﬂ  ow cytom-
etry (D). Megakaryocytes were either unstimulated (no agonist) 
or stimulated for 30 min at room temperature with 1 mM PAR4 
agonist peptide (AYPGFK) or a combination of AYPGFK, 
50   μ  M ADP, and 50   μ  M epinephrine. Fibrinogen binding 
is expressed as fold increase compared with unstimulated 
megakaryocytes transduced with control shRNA. Data are 
means   ±   SEM (error bars) of three experiments.     1219  RIAM, TALIN, AND INTEGRIN ACTIVATION   • Watanabe et al. 
inside-out    IIb   3 signaling in heterologous cells, the major 
conclusions are (1)    IIb   3 activation initiated through platelet 
PAR thrombin receptors requires the recruitment of talin to 
   IIb   3, a process regulated by the Rap1 effector, RIAM; (2) 
RIAM is required for agonist-induced activation of    IIb  3  in 
primary megakaryocytes; (3) in platelets, RIAM is present in 
platelets within fi  lopodia and lamellipodia, subcellular locales 
where integrin activation would be expected to take place; and 
(4) lamellipodin can promote talin recruitment and    IIb  3  acti-
vation in CHO cells; however, unlike RIAM, it may not func-
tion downstream of Rap1 and is not detectable in megakaryocytes 
or platelets. Given the central role of    IIb   3 activation in plate-
let function (  Shattil and Newman, 2004; Jackson, 2007  ), these 
fi  ndings have implications for hemostasis or thrombosis. 
  Signal transduction from PARs or other agonist receptors to 
   IIb   3 involves a network of protein  –  protein interactions and 
posttranslational modifi  cations (  Brass, 2004  ). The inherent com-
plexity of mammalian signaling networks need not preclude even-
tual identifi  cation of all essential elements. Global analyses of the 
platelet transcriptome and proteome are contributing toward this 
goal (  Garcia et al., 2005  ;   Maguire et al., 2005; Gnatenko et al., 
2006  ), but formal characterization of candidate proteins will re-
quire additional strategies. Our approach here was to attempt to 
fully reconstitute and analyze a thrombin-induced    IIb  3  activa-
tion pathway in CHO cells and characterize proteins within this 
pathway in platelets and megakaryocytes. The starting point for 
this study was the observation that transient overexpression of 
full-length mouse talin in   IIb  3-CHO cells is suffi  cient to induce 
   IIb  3 activation in response to overexpression of activated Rap1a 
or RIAM (  Han et al., 2006  ). However, CHO cells are inherently 
unresponsive to thrombin or other platelet agonists, leaving the 
role of RIAM in agonist-induced    IIb   3 activation unclear. 
  This issue was resolved here by coexpressing talin in 
   IIb   3-CHO cells with either human PAR1 or murine PAR4, 
the dominant platelet PARs in these species (  Kahn et al., 1999  ; 
  Sambrano et al., 2001  ). In some experiments, PAR1 and talin were 
expressed in a tetracycline-regulatable fashion to gain better con-
trol of overexpression levels and to limit prolonged contact of the 
PARs with thrombin or other proteases in serum to avoid desensi-
tization (  Hoxie et al., 1993  ;   Kahn et al., 1999  ;   Kuliopulos et al., 
1999 ). Under these conditions, thrombin or highly specifi  c agonist 
peptides for PAR1 or PAR4 (  Vu et al., 1991; Faruqi et al., 2000  ) 
stimulated    IIb   3 activation, as measured by binding of the 
ligand-mimetic antibody, PAC-1, the antibody generally used to 
study    IIb  3  affi  nity modulation in human platelets (  Michelson, 
2006  ). Using shRNA to partially knock down specifi  c proteins, 
RIAM was identifi  ed as a necessary distal element of the thrombin-
mediated and talin-driven    IIb   3 activation machinery both in 
the CHO model system and megakaryocytes. Thus, it should now 
be possible to identify and order other essential PAR pathway 
components, some of which may be Rap1 dependent and others 
Rap1 independent (  Coughlin, 2000; Brass, 2004  ). PARs in plate-
lets also signal to activate the integrin    2  1  collagen  receptor 
(  Jung and Moroi, 2001  ). Because PARs and    2   1 are widely ex-
pressed (  Coughlin, 2000; Chen et al., 2002  ), the approaches taken 
here to probe    IIb   3 activation may be useful in characterizing 
inside-out integrin signaling in other biological contexts. 
  In model cells, including CHO cells, overexpression of the 
talin head or FERM domain leads to activation of    1,     2, and    3 
integrins (  Calderwood et al., 1999  ;   Kim et al., 2003  ;   Tadokoro 
et al., 2003; Ma et al., 2006  ;   Bouaouina et al., 2008  ). Because 
talin normally resides in the cytoplasm of unstimulated platelets 
( Bertagnolli et al., 1993 ), agonist stimulation is thought to induce 
posttranslational and conformational modifi  cations within talin 
to expose integrin-binding sites, resulting in talin recruitment 
to integrin cytoplasmic domains and inside-out integrin activa-
tion (  Calderwood, 2004  ;   Critchley, 2004  ;   Ginsberg et al., 2005  ). 
We propose that it is RIAM that mediates talin recruitment to 
   IIb   3 in platelets. First, when Rap1a (V12), RIAM, and talin 
are overexpressed in CHO cells, RIAM coimmunoprecipitates 
and colocalizes with talin (  Han et al., 2006  ). Second, RIAM 
  coimmunoprecipitates with talin after human platelets are stimu-
lated by a PAR1 agonist (  Han et al., 2006  ). Third, Rap1a (V12) 
and RIAM promoted talin recruitment to    IIb   3 in living cells, 
as demonstrated here by BiFC (  Figs. 2 and 3  ). Fourth, there was 
tight linkage between talin recruitment and    IIb  3  activation, 
and mutants in either talin or     3 that abrogate their mutual 
inter  action blocked both responses (  Fig. 2  ). Finally, RIAM was 
strategically localized in platelets for a role in    IIb  3  activation 
(  Fig. 6 A  ), and RIAM knockdown inhibited agonist-induced 
   IIb   3 activation in megakaryocytes (  Fig. 6 D  ). 
 In  fi  broblasts, lamellipodin regulates lamellipodia formation 
and protrusion velocity through interactions with Ena/VASP and 
other effectors ( Krause et al., 2004 ). Lamellipodin does not appear 
to be a Rap1 effector and may even function to reduce adhesion 
of Jurkat T lymphocytes via    1  integrins  ( Krause  et  al.,  2004 ; 
  Lafuente et al., 2004  ). The domain compositions of RIAM and 
lamellipodin are similar. We found that overexpression of lamelli-
podin in CHO cells increased talin recruitment and    IIb  3  activa-
tion ( Fig. 3 ), and lamellipodin knockdown reduced PAR1-mediated 
   IIb   3 activation, albeit less effectively than RIAM knockdown 
(  Fig. 5  ). Although we could not detect lamellipodin protein 
in platelets or megakaryocytes, further studies of lamellipodin/
integrin relationships in other cells appear to be warranted. 
  We chose BiFC as a method to study talin recruitment to 
   IIb   3 in living cells because of its ease of implementation, its 
facile adaptation to standard fl  uorescence microscopy and fl  ow 
  cytometry (  Kerppola, 2008  ), and our previous success with the 
method in analyzing integrin  –  protein tyrosine kinase interactions 
(  de Virgilio et al., 2004  ). Potential drawbacks of BiFC compared 
with other methods, such as FRET, are delayed maturation of the 
reconstituted split fl  uorophore and possible stabilization of the pro-
tein  –  protein interaction under study (  Shyu et al., 2006; Kerppola, 
2008 ). Although this makes BiFC unsuitable for assessing dynamic 
changes in protein interactions, any secondary stabilization of the 
talin –   IIb   3 interaction may have proved useful in our case by 
also stabilizing the high-affi  nity state of   IIb  3 and, thus, its detec-
tion with PAC-1. Recently, FRET was used to cleverly monitor the 
activation state of     1 integrins (  Parsons et al., 2008  ). There, the    1 
subunit was tagged with GFP, and the isolated talin rod domain was 
tagged with mRFP. Addition of     1 extracellular ligands induced 
the association of     1 integrin with the talin rod (  Parsons et al., 
2008  ), which is consistent with previous observations that the 
binding of adhesive ligands activates integrins (  Du et al., 1991  ). JCB • VOLUME 181 • NUMBER 7 • 2008  1220 
manufacturer  ’  s recommendations. To produce stable cell lines, CHO cells were 
transfected with the appropriate expression plasmids. 48 h later, antibiotics 
for selection were added, and cells were cultured for     2 wk. Clones were 
selected further by single-cell sorting using MoFlo (Dako), and stable ex-
pression of recombinant proteins was conﬁ  rmed by ﬂ  ow cytometry or Western 
blotting. In some cases, stable CHO cell clones capable of tetracycline-inducible 
expression of PAR1 and/or talin were produced (  Yao et al., 1998  ). 
  Lentivirus production and infection 
  Plasmids encoding shRNA for mouse RIAM and the human U6 promoter 
(  Han et al., 2006  ) were ampliﬁ  ed by PCR to place XbaI and XhoI sites, and 
PCR products were cloned into lentiviral vector FG12 (  Qin et al., 2003  ). 
Promoter and shRNA sequences were conﬁ  rmed by DNA sequencing. 
shRNAs for mouse and rat lamellipodin with mouse U6 promoter fragments 
(  Krause et al., 2004  ) were removed at XbaI and XhoI sites from the pLL3.7 
vector and cloned into FG12. Control shRNA was obtained from a scram-
bled sequence of mRNA derived from Rock1 (  Tadokoro et al., 2003  ). 
  Viruses were produced by calcium phosphate  –  mediated transient 
transfection of 293T cells. The cells were triple transfected with plasmid 
FG12 encoding shRNA, envelope plasmid pCI  –  vesicular stomatitis virus G 
protein, and packaging plasmid pCMV    R8.91. Viruses were collected as 
conditioned medium 3 d after transfection, and viral titers were determined 
by measuring GFP expression in infected NIH3T3 cells. Titers ranged from 
0.3 to 10 
7   U/ml. To achieve protein knockdown, CHO cells were incu-
bated for 16 h with 8   μ  g/ml Polybrene (Sigma-Aldrich) and lentivirus-
  containing medium at a multiplicity of infection of ﬁ  ve. After further culture 
in complete DME, cells were studied as described in each experiment. 
  Flow cytometry 
      IIb    3 activation was assessed by ligand-mimetic antibody PAC-1 (  Shattil 
et al., 1985  ) 96 h after lentiviral infection with shRNAs and 48 h after 
transient transfection with expression plasmids. For tetracycline-inducible 
expression of PAR1 and/or talin, cells were incubated with doxycycline 
(Sigma-Aldrich) for 24 h. PAC-1 binding and     IIb    3 surface expression 
were determined by incubating cells with 0.4% PAC-1 ascites or 0.25% anti-
body D57, respectively, for 10 min at room temperature. To study agonist-
induced     IIb    3 activation in CHO cells expressing PAR1, the cells were 
incubated in duplicate or triplicate with PAR1 agonist peptide SFLLRN dur-
ing the PAC-1 incubation phase. After washing the cells, AlexaFluor647-
conjugated anti  –  mouse IgM (for PAC-1) or anti  –  mouse IgG (for D57) was 
added for 20 min at 4  °  C, and antibody binding to living (propidium iodide 
negative) cells was determined by ﬂ  ow cytometry using a dual-laser FACS-
Calibur and Cell Quest software (BD Biosciences;   O  ’  Toole et al., 1994  ). 
Cells transiently transfected with expression plasmids or transduced with 
shRNAs were typically identiﬁ  ed and gated in the ﬂ  ow cytometer by their 
GFP or td-Tomato ﬂ  uorescence. Speciﬁ  c PAC-1 binding was normalized 
for     IIb    3 expression and deﬁ  ned as (sample PAC-1 binding)      (PAC-1 
binding with 5 mM EDTA)/(sample D57 staining). Speciﬁ  c PAC-1 binding 
generally represented   >  85% of total binding. Surface expression of recom-
binant PAR1 or PAR4 was measured by ﬂ  ow cytometry using an antibody 
speciﬁ  c for the Flag epitope. Talin expression was assessed by ﬂ  ow cytometry 
after cell ﬁ  xation, permeabilization, and intracellular staining with anti-
body 8d4 as described previously (  Tadokoro et al., 2003  ). 
  Interactions between     IIb    3 and talin in living cells 
  The chimeric proteins used for BiFC experiments and the rationale for these 
experiments are depicted in   Fig. 1 A  . BiFC Venus vectors were provided by 
C.-D. Hu (Purdue University, West Lafayette, IN;   Shyu et al., 2006  ). A plas-
mid template encoding the C-terminal half of Venus (VC) was ampliﬁ  ed by 
PCR to place appropriate restriction sites, and the PCR product was in-
serted in-frame at the 3     end of     IIb in pcDNA3.1 (Invitrogen) to form     IIb-VC. 
The N-terminal half of Venus (VN) was ampliﬁ  ed to place appropriate 
  restriction sites, and the PCR product was inserted in-frame into the 5     end 
of talin cDNA in pcDNA3.1 to form VN-talin. For inducible expression, 
VN-talin was subcloned into pcDNA4/TO. cDNAs encoding wild-type     3 
and     3 (    724) were cloned into pcDNA3.1. VN-talin mutants (L325R and 
W359A) and the     3 (Y747A) mutant were created from wild-type cDNAs 
by mutagenesis (QuikChange Mutagenesis kit; QIAGEN). All coding se-
quences were conﬁ  rmed by DNA sequencing. Plasmid encoding     IIb-VC 
was cotransfected with     3,     3 (    724), or     3 (Y747A) into CHO cells with 
Lipofectamine. 48 h later, cells were cultured in the presence of G418 (In-
vitrogen) for 2 wk. Clones stably expressing the recombinant integrin were 
obtained by single-cell FACS sorting using anti-    IIb    3 antibody D57. For 
some experiments, cells capable of the inducible expression of VN-talin were 
obtained by transfection of stable     IIb-VC    3  –  CHO cells with pcDNA6/TR 
(repressor plasmid) and pcDNA4/TO/VN-talin and selection with Zeocin 
Interestingly, interaction of the isolated talin head domain with 
    1 integrin could not be demonstrated by FRET, possibly because 
of fl  uorophore orientation. Although inside-out integrin signaling 
was not evaluated in the FRET study, it is apparent that FRET 
and BiFC will provide powerful complementary approaches to 
study integrin signaling and, in particular, to characterize newly 
identifi  ed effectors of integrin function (  Moser et al., 2008  ). 
 Identifi  cation of a functional RIAM  –  talin  –  integrin axis in 
platelets may provide new insights into clinical disorders of 
hemostasis or thrombosis. On one hand, there are several poorly 
understood bleeding disorders associated with defects in    IIb  3 
activation (  Rao et al., 2004  ). Some may now be explained by ab-
normalities in this axis. As a recent example, patients have been 
described with recurrent bleeding and infections and defective 
  agonist-induced integrin activation in platelets and white blood 
cells attributable to a defi  ciency of the Rap1 exchange factor 
CalDAG-GEFI (  Pasvolsky et al., 2007  ). On the other hand, exces-
sive or inappropriate    IIb   3 activation may complicate athero-
thrombosis and other diseases (  Ruggeri, 2002; Michiels et al., 
2006  ). Current oral antiplatelet agents, such as aspirin and ADP 
receptor antagonists, are only partially effective in reducing 
  arterial thrombosis in humans (  Bhatt and Topol, 2003  ). Thus, 
there is an unmet need for more effective, long-term platelet 
function blockade, and oral    IIb   3 antagonists have not proven 
useful in this regard (  Bhatt and Topol, 2003  ). Accordingly, 
RIAM and talin, by virtue of their central roles in a fi  nal com-
mon pathway of inside-out    IIb   3 activation, provide potential 
targets for new antithrombotic drugs. 
  Materials and methods 
  Reagents and plasmid vectors 
  Agonist peptides speciﬁ  c for human PAR1 (SFLLRN;   Vu et al., 1991  ) and mu-
rine PAR4 (AYPGKF;   Faruqi et al., 2000  ) were synthesized and puriﬁ  ed by the 
Scripps Center for Protein Sciences. Antibodies speciﬁ  c for RIAM and lamelli-
podin were described previously (  Krause et al., 2004  ;   Lafuente et al., 2004  ). 
R-phycoerythrin  –  conjugated rat anti  –  mouse CD41 antibody (MWReg30) was 
purchased from BD Biosciences. Antibody to human integrin     3 was obtained 
from Santa Cruz Biotechnology, Inc. Antibody to mouse glycoprotein IX 
(Xia.B4) was obtained from Emfret. Antibody to     -actin was purchased from 
Abcam. Antibodies to talin (8d4), vinculin (VIN-11-5), and the Flag epitope 
were purchased from Sigma-Aldrich. Antibody to the inﬂ  uenza hemagglutinin 
HA-1 epitope was purchased from Covance Research Products. 
  Plasmids encoding cDNAs for mouse talin1 (  Han et al., 2006  ), hu-
man PAR1 (  Kahn et al., 1999  ), and mouse PAR4 (  Kahn et al., 1998  ) have 
been described previously. cDNAs were subcloned into the pcDNA4/TO 
tetracycline-inducible expression vector (Invitrogen). Plasmid encoding td-
Tomato (pREST/tdTomato; gift from R. Tsien, University of California, San 
Diego, La Jolla, CA;   Shaner et al., 2004  ) was subcloned along with the 
  internal ribosomal entry site (IRES) from pIRES-GFP2 (Invitrogen) into pEF4/
Myc-His-A (Invitrogen) to construct the pEF4/IRES-tdTomato mammalian ex-
pression vector. Also, IRES-GFP from the pIRES-GFP2 vector was subcloned 
into pEF4/Myc-His-A to construct pEF4/IRES-GFP. Mammalian expression 
vectors for HA-Rap1a (V12) and HA-Rap1GAP were gifts from J. Bos (Uni-
versity Medical Center Utrecht, Utrecht, Netherlands) and A. Hall (Memo-
rial Sloan-Kettering, New York, NY), respectively. The coding regions of 
HA-Rap1a (V12) and HA-Rap1GAP were ampliﬁ  ed by PCR to place ap-
propriate restriction sites, and PCR products were subcloned downstream of 
the EF-1     promoter into pEF4/IRES-tdTomato. Similarly, RIAM and lamelli-
podin cDNAs (  Krause et al., 2004  ;   Lafuente et al., 2004  ) were cloned into 
pEF4/IRES-tdTomato and pEF4/IRES-GFP. 
  Cell culture and transfection 
  CHO-K1, 293T, and NIH3T3 cells were cultured in DME and supplemented 
with antibiotics, nonessential amino acids,   L-  glutamine, and 10% FBS. For tran-
sient transfections, Lipofectamine (Invitrogen) was used according to the 1221  RIAM, TALIN, AND INTEGRIN ACTIVATION   • Watanabe et al. 
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and Blasticidin (Invitrogen) for 2 wk. Then, cells were incubated with or 
without 1   μ  g doxycycline for 24 h and selected by single-cell FACS sorting 
for BiFC ﬂ  uorescence resulting from high coexpression of VN-talin and     IIb-
VC    3. BiFC experiments were typically conducted by ﬂ  ow cytometry to 
  enable simultaneous measurement of PAC-1 binding. 
  Deconvolution microscopy 
      IIb-VC    3  –  CHO and     IIb-VC    3 (    724) cells were cotransfected with VN-
talin and Rap1a (V12) and, 48 h later, were allowed to spread for 1 h on 
ﬁ   brinogen-coated glass coverslips (100-  μ  g/ml coating concentration). 
Washed human platelets were plated on ﬁ  brinogen-coated coverslips for 
up to 45 min. After washing with PBS, pH 7.4, adherent cells were ﬁ  xed 
with 4% PFA in PBS, permeabilized with 0.2% Triton X-100 in PBS, and 
blocked with 10% goat serum in PBS. Cells were stained sequentially with 
antivinculin antibody and AlexaFluor548-conjugated secondary antibody. 
Images were captured at room temperature on a deconvolution microscope 
(DeltaVision; Applied Precision) using a charged-coupled device camera 
system (CoolSNAP HQ; Photometrics) attached to an inverted wide-ﬁ  eld 
ﬂ  uorescence microscope (Eclipse TE200; Nikon) equipped with 40  ×   and 
100  ×   oil-immersion objectives (Nikon). Identical software settings were 
used for image acquisition of all samples in a given experiment, and im-
ages were deconvoluted with an iterative-constrained algorithm. Cell ﬂ  uor-
escence intensity range was standardized using the Softworks Analysis 
Program (Applied Precision). Any further adjustments of color balance 
made with Photoshop CS3 software (Adobe) were applied to the entire im-
age in a ﬁ  gure, and no nonlinear adjustments were made. 
  Western blotting 
  Cells were lysed with NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 1% NP-
40, 150 mM NaCl, 1 mM NaF, 0.5 mM sodium vanadate, 12.5   μ  g/ml leu-
peptin, and Complete EDTA free [Roche]). After clariﬁ  cation, cell lysates 
were subjected to SDS-PAGE and transferred to nitrocellulose membranes 
(Bio-Rad Laboratories). Membranes were blocked with 3% BSA in TBS with 
0.1% Tween 20 and incubated for 1 h each with primary antibodies and 
IRDye 680  –   or IRDye 800CW  –  conjugated secondary antibodies (LI-COR 
Biotechnology). Antibody binding was detected with the Odyssey system 
(LI-COR Biotechnology). Band density was quantiﬁ  ed on a Pro computer 
(Macintosh) with ImageJ 1.39m software (National Institutes of Health). 
  Fibrinogen binding to murine megakaryocytes 
  Mouse R1 embryonic stem cells were cultured with OP9 stromal cells under 
conditions that yield megakaryocytes capable of binding ﬁ  brinogen in re-
sponse to platelet agonists (  Eto et al., 2003  ). After5 d in culture, nonadher-
ent hematopoietic progenitors were exposed for 16 h to lentivirus encoding 
RIAM shRNA or control shRNA and were cultured on a fresh OP9 layer for 
an additional 7 d as described previously (  Eto et al., 2003  ) to induce mega-
karyocyte differentiation. Megakaryocytes were collected by sedimenta-
tion and incubated with biotin-ﬁ  brinogen and R-phycoerythrin  –  streptavidin 
(Invitrogen) in the presence or absence of platelet agonists for 30 min (  Eto 
et al., 2003  ). Intermediate-sized and large megakaryocytes were gated in a 
ﬂ  ow cytometer on the basis of forward light scatter, and speciﬁ  c ﬁ  brinogen 
binding, which is deﬁ  ned as binding inhibitable with 5 mM EDTA, was 
measured (  Shiraga et al., 1999; Eto et al., 2003  ). 
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